COMPASS Pathways (NASDAQ: CMPS) is one of 886 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare COMPASS Pathways to related companies based on the strength of its institutional ownership, dividends, risk, earnings, analyst recommendations, profitability and valuation.
This table compares COMPASS Pathways and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|COMPASS Pathways Competitors||-3,674.62%||-115.85%||-26.81%|
This table compares COMPASS Pathways and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|COMPASS Pathways||N/A||-$60.33 million||-8.98|
|COMPASS Pathways Competitors||$1.70 billion||$122.33 million||-2.41|
COMPASS Pathways’ peers have higher revenue and earnings than COMPASS Pathways. COMPASS Pathways is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current recommendations and price targets for COMPASS Pathways and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|COMPASS Pathways Competitors||4985||18508||40311||777||2.57|
COMPASS Pathways currently has a consensus price target of $75.14, suggesting a potential upside of 135.71%. As a group, “Pharmaceutical preparations” companies have a potential upside of 57.38%. Given COMPASS Pathways’ stronger consensus rating and higher possible upside, equities research analysts clearly believe COMPASS Pathways is more favorable than its peers.
Institutional and Insider Ownership
18.7% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 44.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.4% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
COMPASS Pathways peers beat COMPASS Pathways on 7 of the 12 factors compared.
COMPASS Pathways Company Profile
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.